News

Nerve growth factor gene therapy delivered safely in Alzheimer’s patients

Publish date: November 21, 2013

 

AT CTAD

The phase 1 study was funded by Ceregene, which was acquired in October 2013 by Sangamo BioSciences.

Dr. Bartus disclosed that he is a consultant for Sangamo BioSciences.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Fibromyalgia patients may harbor fewer small-nerve fibers
MDedge Internal Medicine
Maternal lupus doubled autism risk
MDedge Internal Medicine
Number of restless leg movements during sleep may predict AFib progression
MDedge Internal Medicine
FDA approves eslicarbazepine as an adjunctive partial seizure treatment
MDedge Internal Medicine
Oxycodone-naloxone nips RLS symptoms after other treatment failures
MDedge Internal Medicine
Small study: TBI leads to rapid deposition of brain amyloid
MDedge Internal Medicine
FDA panel has mixed votes on alemtuzumab for multiple sclerosis
MDedge Internal Medicine
Capsaicin 8% patch offers relief for brachioradial pruritus
MDedge Internal Medicine
FDA approves neurostimulator device for treatment-resistant epilepsy
MDedge Internal Medicine
Headache neuroimaging and medication no-nos highlighted in new list
MDedge Internal Medicine